Diadem is a platform therapeutics company developing immunotherapies. Its cell-secreted nanovesicles are engineered to deliver signals that mimic natural cell-to-cell signaling. Diadem's approach enables modulation of targets that play a role in chronic inflammation, autoimmune diseases, and immune control of cancers, according to the firm.

The company also will receive mentoring from scientific and business leaders at Amgen and other facility benefits. Diadem is the first winner of the three-year sponsored competition.

The goal of the award is to support life science startups in the development of new therapies, medical devices, and diagnostics.

Amgen to buy private firm Teneobio for $900M
Amgen will spend $900 million in cash to acquire the privately held biotechnology company Teneobio, which is developing a new class of biologics...

Amgen to acquire Five Prime Therapeutics for $1.9B
Amgen has agreed to acquire Five Prime Therapeutics for approximately $1.9 billion, adding Five Prime's pipeline of therapeutic antibodies to its...

Amgen to sponsor Golden Ticket award at BioLabs LA
Amgen is sponsoring a three-year Golden Ticket award at BioLabs LA at the Lundquist Institute in West Carson, CA, to support the development of new therapies,...

Top biopharma companies form data exchange nonprofit
Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions...

Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.